Nimitt Consulting’s mission is to ensure that providers can care for their patients in the best way possible—and get reasonable reimbursement for their services. Our Perspectives page reflects Nimitt’s passion and commitment to advocacy and education.
Nimitt’s advocacy articles help educate policymakers and empower providers to share their experiences and insights in order to ensure that regulations support the front-line realities of modern health care. Our provider education series focuses on key coverage, coding, billing, and reimbursement implementation and operations issues, with a particular lens towards compliance and margin preservation.
Please share your thoughts on topics of interest and follow us on LinkedIn for more of our Perspective pieces.
Most payers are legally required to cover routine costs related to clinical trial treatment. In this article, Nimitt recommends that hospitals familiarize themselves with these requirements, which will support reimbursement and access to clinical trials that is timely and equitable.
Four new AMA-approved CPT® codes for CAR-T cell collection, cell processing (outbound and inbound), and administration (3X018-3X021) go into effect on 1/1/2025. Nimitt created this article to help providers advocate for CMS to MPFS recognition of separate payment for CAR-T cell collection and cell processing services provided in both the hospital setting and free-standing physician offices.
Four new AMA-approved CPT® codes for CAR-T cell collection, cell processing (outbound and inbound), and administration (3X018-3X021) go into effect on 1/1 2025. Nimitt created this article to help providers advocate for CMS to provide hospitals with OPPS payment for outpatient CAR-T cell collection and cell processing services to ensure appropriate payment is provided to hospitals for the clinical services provided to patients.
Most Medicare beneficiaries are enrolled in Medicare Advantage (MA) plans, but MA claims are not used in Medicare rate-setting. It is imperative for stakeholders to have access to MA data along with Medicare fee-for-service (FFS) data to improve the rate-setting process. Nimitt created this article to help providers advocate for access to MA claims data and encourage CMS to study the impact of MA claims’ exclusion on FFS rate-setting.
CMS’ new Cell and Gene Therapy (CGT) Access Model seeks to test whether outcomes-based agreements improve access to transformative CGTs for beneficiaries with sickle cell disease. In this article, Nimitt discusses the need for CMS to address challenges created by Medicaid out-of-state provider enrollment regulations, which present often-insurmountable barriers to care.
In the 2024 MPFS final rule, CMS created four new codes and payments for services designed to improve patient health: social determinants of health, principal illness navigation, community health integration, and caregiver training services. In this article, Nimitt summarizes the codes, their use, payment rates, and raises some key implementation questions.
Site neutral payment policies do not achieve the goal of addressing the nation’s astronomical health care costs. Instead, they will harm patients and providers alike and exacerbate hospital closures, particularly in rural and urban areas with reduced access to facilities. Nimitt wrote this article to highlight these policies’ problematic results and present viable alternatives.